首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Influence of Differently Licensed KIR2DL1-Positive Natural Killer Cells in Transplant Recipients with Acute Leukemia: A Japanese National Registry Study
【24h】

Influence of Differently Licensed KIR2DL1-Positive Natural Killer Cells in Transplant Recipients with Acute Leukemia: A Japanese National Registry Study

机译:不同许可的KIR2DL1阳性自然杀伤细胞对移植性急性白血病患者的影响:日本国家注册研究

获取原文
获取原文并翻译 | 示例
       

摘要

Licensing by self MHC class I ligands is required for proper natural killer (NK) cell response. NK cells with inhibitory killer cell immunoglobulin-like receptors for nonself MHC exhibit transient alloreactivity after hematopoietic stem cell transplantation (HSCT). We analyzed 3866 recipients in the Japan national registry who underwent their first allogeneic HSCT for acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) from HLA-A, -B, and -DRB1 allele-genomatched unrelated donors. By classifying them into 5 independent groups based on HLA-C group matching and assumed donor NK cell status, we found that for HLA-C matched HSCT for AML in HLA-C1/C1 recipients, in whom transient alloreactivity against HLA-C2 negative leukemic cells was expected, the relapse rate was significantly lower than it was in HLA-C matched HSCT for AML in HLA-C1/C2 recipients (hazard ratio [HR], .72; P = .011). This difference was not observed in HLA-C matched HSCT for ALL. Compared with HLA-C-matched HSCT, significantly higher mortality was observed in HLA-C1/C1 AML patients who received transplants from HLA-C mismatched HLA-C1/C1 donors (HR, 1.37; P = .001) and in HLA-C1/C1 ALL patients who received transplants from HLA-C2 positive donors (HR, 2.13; P = .005). In conclusion, donor selection based on leukemic subtype and donor HLA-C group matching improves transplantation outcome after HLA-C mismatched HSCT. (C) 2016 American Society for Blood and Marrow Transplantation.
机译:适当的自然杀伤(NK)细胞反应需要通过自身的MHC I类配体进行许可。具有非自身MHC抑制性杀伤细胞免疫球蛋白样受体的NK细胞在造血干细胞移植(HSCT)后表现出短暂的同种异体反应。我们分析了日本国家登记册中3866名接受过首次同种异体HSCT的,来自HLA-A,-B和-DRB1等位基因-基因匹配的无关供者的急性骨髓性白血病(AML)或急性淋巴细胞性白血病(ALL)的接受者。通过基于HLA-C组匹配和假定的供体NK细胞状态将它们分为5个独立的组,我们发现,对于HLA-C1 / C1受体,HLA-C与HSCT匹配的AML AML,其中针对HLA-C2阴性白血病的瞬时同种反应性在HLA-C1 / C2接受者中,AML的复发率明显低于AML的HLA-C匹配HSCT(危险比[HR],0.72; P = .011)。在ALL的HLA-C匹配HSCT中未观察到这种差异。与HLA-C匹配的HSCT相比,接受HLA-C不匹配的HLA-C1 / C1供体移植的HLA-C1 / C1 AML患者(HR,1.37; P = .001)和HLA-从HLA-C2阳性供体接受移植的C1 / C1 ALL患者(HR,2.13; P = .005)。总之,基于白血病亚型和供体HLA-C组匹配的供体选择可改善HLA-C不匹配HSCT后的移植结果。 (C)2016美国血液和骨髓移植学会。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号